Clearside Biomedical launches Phase II diabetic macular edema trial

Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the first patient in a Phase II clinical trial of CLS-TA in patients with diabetic macular edema.
The trial plans to evaluate Clearside’s suspension formulation of a corticosteroid, triamcinolone acetonide, as a suprachoroidal injection in combination with an intravitreal injection of Eylea, an anti-VEGF agent.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical launches Phase II diabetic macular edema trial appeared first on MassDevice.

Source: Mass Device - July 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news